Last reviewed · How we verify

NCT04216095

Comparative Effectiveness Clinical Trial of MST Compared to ECT in Major Depressive Disorder

Completed Phase 2, PHASE3 Last updated 3 January 2020
What this trial tests

Phase 2, PHASE3 trial testing Electroconvulsive Therapy (n=30) in Major Depressive Disorder in 60 participants. Completed in 7 October 2015.

Timeline
7 June 2013
Primary endpoint
7 October 2015
7 October 2015

Quick facts

Lead sponsorTanta University
PhasePhase 2, PHASE3
StatusCompleted
Study typeINTERVENTIONAL
Allocationnon randomized
Designparallel
Maskingnone
Primary purposetreatment
Enrollment60
Start date7 June 2013
Primary completion7 October 2015
Estimated completion7 October 2015

Drugs / interventions tested

Conditions studied

Sponsor

Tanta University

Who can join

Adults 18 to 65, any sex, with Major Depressive Disorder. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study was a prospective, open-label comparative effectiveness clinical trial, comparing magnetic seizure therapy (MST) to ECT in patients with Major Depressive Disorder (MDD).

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Major Depressive Disorder

Currently open trials in the same condition.

Other Tanta University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04216095.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing